The 18.7 Data Release includes additional metabolomic data, sequencing data, and a computational pipeline for human studies.


  • The  ROSMAP Study

    This study provides genomic, transcriptomic, epigenetic, proteomic, and metabolomic data on individuals as part of the Religious Orders Study (ROS) and the Memory and Aging Project (MAP) enrolled by the Rush Alzheimer’s Disease Center.

    • This release adds metabolomic data from dorsolateral prefrontal cortex samples of 514 donors analyzed on the Metabolon HD4 platform. Quantified metabolites include amino acids, carbohydrates, cofactors and vitamins, fatty acids, nucleotides, peptides, and xenobiotics.
    • This release also provides updated biospecimen and assay metadata for existing ROSMAP metabolomics data in the AD Portal. ROSMAP brain and serum samples from which data was previously generated via a UPLC-MSMS protocol and the Biocrates p180 platform are now included in the study metadata files.
  • The ADMC_ADNI_NightingaleNMR Study

    This study provides metabolomics data generated on the Nightingale Health NMR Platform from serum from the Alzheimer’s Disease Neuroimaging Initiative – 1, GO, and 2 cohorts. Quantified metabolites include lipoproteins, fatty acids, glycerides, phospholipids, amino acids, ketones, and cholesterol.

    • This release provides 4891 additional longitudinal Nightingale metabolomics samples from the ADNI cohort.
  • The ROSMAP_bsSeq Study

    This study provides targeted bisulfite sequencing data from brain tissue obtained from 150 randomly selected participants from the ROSMAP cohort, and the results of Expression Wide Association Study (EWAS) analyses between expression data and six AD-related traits.

    • The EWASplus pipeline for predicting novel AD-associated CpG sites is also available as a computational tool on the AD Portal.